A5108419934- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Polyomavirus and related diseases
- Immune Cell Function and Interaction
- Renal Transplantation Outcomes and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- Transplantation: Methods and Outcomes
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Chemotherapy-induced cardiotoxicity and mitigation
- Brain Metastases and Treatment
- Histone Deacetylase Inhibitors Research
- Cancer Treatment and Pharmacology
- Glycosylation and Glycoproteins Research
- Mesenchymal stem cell research
- Cancer survivorship and care
- Dialysis and Renal Disease Management
Case Western Reserve University
2013-2024
Universidade Federal de Sergipe
2024
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2023
The University of Texas MD Anderson Cancer Center
2005-2017
University Hospitals of Cleveland
2017
University Hospitals Cleveland Medical Center
2013-2015
Fred Hutch Cancer Center
2014
Sidney Kimmel Comprehensive Cancer Center
2014
Johns Hopkins University
2014
Cancer Research Center
2014
Purpose The clinical safety and efficacy of intravenous busulfan fludarabine (IV Bu/Flu) myeloablative conditioning as well graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies. We hypothesized that combining these two promising approaches a multi-institutional study human leukocyte antigen (HLA) -matched bone marrow transplantation would provide low rates severe...
Summary Chronic graft‐ versus ‐host disease (cGVHD) remains a major cause of morbidity and mortality in haematopoietic transplant recipients. Sirolimus is macrocyclic triene antibiotic with immunosuppressive, antifungal antitumour properties, that has activity the prevention treatment acute GVHD. We conducted phase II trial sirolimus combined tacrolimus methylprednisolone patients steroid‐resistant cGVHD. Thirty‐five who developed GVHD after day 100 post‐transplant were studied. Six had...
We evaluated outcomes and associated prognostic factors in 233 patients undergoing allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis (MF) using reduced-intensity conditioning (RIC). The median age at RIC HCT was 55 yr. Donors were a matched sibling donor (MSD) 34% of HCTs, an HLA well-matched unrelated (URD) 45%, partially matched/mismatched URD 21%. Risk stratification according to the Dynamic International Prognostic Scoring System (DIPSS) 12% low, 49%...
We evaluated the feasibility and efficacy of a reduced-intensity conditioning (RIC) regimen fludarabine melphalan to achieve rapid complete donor chimerism after allogeneic stem cell transplantation (SCT) in patients with metastatic solid tumors. Between January 1999 2003, 8 breast cancer (BC) 15 renal carcinoma (RCC) underwent SCT an RIC 5 days 2 melphalan. Filgrastim-mobilized cells from HLA-identical related or unrelated donors were infused. Prophylaxis for graft-versus-host disease...
Summary Major ABO mismatching is not considered a contraindication to allogeneic haematopoietic stem cell transplantation ( HSCT ). Modern reduced‐intensity conditioning and reduced‐toxicity regimens cause much less myeloablation than conventional myeloablative regimens, such as cyclophosphamide with busulfan or total body irradiation, which may affect the incidence of pure red aplasia PRCA We estimated described natural history in patients major ‐mismatched donor cells. Between 2007 2008,...
Autologous chimeric antigen receptor-modified T-cell (CAR T) products have demonstrated un-precedent efficacy in treating many relapsed/refractory B-cell and plasma cell malignancies, leading to multiple commercial now routine clinical use. These positive responses CAR T therapy spurred biotech big pharma companies evaluate innovative production methods increase patient access while maintaining adequate quality control profitability. cellular therapies are, by definition, manufactured as...
Cord blood-derived stem cells are successfully used in the treatment of cancer and congenital disorders children. This alternative source is also explored for adult patients with limited donor options. However, delayed engraftment, prolonged neutropenia, secondary graft loss, graft-versus-host disease (GVHD) recipients cord blood transplantation (CBT) make opportunistic infections a serious concern. We evaluated spectrum adults children undergoing CBT at our National Cancer...
Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ≥40 years receiving reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) HCT aggressive (n = 668) indolent 580) NHL. Aggressive was more frequent in the oldest cohort 49% 40 to 54 versus 57% 55 64 67% ≥65; P .0008). Fewer aged ≥65 had...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of that characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature provides an opportunity to examine the role stem cell transplantation in its management. We report here single-center experience 26 patients with relapsed NLPHL treated high-dose chemotherapy autologous between 1990 2008. With median follow-up 50 months (range, 2-138 months), 5-year...
Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after matched unrelated, related, or mismatched related donor hematopoietic stem-cell transplantation (HSCT). Improved GVHD prevention methods are needed. Pentostatin, an adenosine deaminase inhibitor, leads to lymphocyte depletion with low risk myelosuppression. We hypothesized that addition pentostatin prophylaxis tacrolimus mini-methotrexate may improve outcomes, we conducted Bayesian adaptively...
The optimal dose and schedule of thymoglobulin (ATG) for graft-versus-host disease prevention (GVHD) is unknown. We compared two doses ATG (4.5 mg/kg 7.5 mg/kg) in a Bayesian adaptively randomized fashion, assessed whether levels measured on days 0, 7, 14 28 were associated with clinical outcomes. Treatment success was defined as the patient being alive, engrafted, remission without acute GVHD at day 100. Twenty patients received 4.5 (n = 15) or 5) reduced-intensity conditioning followed by...
Complete remission (CR) is the gold standard for assessing outcomes following chemotherapy acute myelogenous leukemia (AML). "CRp," a response criterion defined as fulfillment of all criteria CR except platelet count recovery to ≥100 × 10(9)/L, associated with inferior chemotherapy. The prognostic importance CRp before allogeneic stem cell transplantation (allo-SCT) remains unknown. We analyzed cohort AML (n = 334) and myelodysplastic syndrome (MDS; n 10) patients determine significance...
Abstract The 5‐azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation‐inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), under evaluation as maintenance therapy AML postallogeneic hematopoietic stem cell transplant to treat hemoglobinapathies. Malignant cytoreduction is thought occur by S‐phase specific depletion the key epigenetic regulator, DNA methyltransferase 1 (DNMT1) that, in case cancers, thereby releases...